Diffuse lung involvement in rheumatoid arthritis: a respiratory physician's perspective : Chinese Medical Journal

Secondary Logo

Journal Logo

Review Article

Diffuse lung involvement in rheumatoid arthritis: a respiratory physician's perspective

Huang, Hui1; Chen, Ruxuan1; Shao, Chi1; Xu, Zuojun1; Wolters, Paul J.2

Editor(s): Wei, Peifang; Pan, Xiangxiang

Author Information
Chinese Medical Journal ():10.1097/CM9.0000000000002577, January 20, 2023. | DOI: 10.1097/CM9.0000000000002577
  • Open
  • PAP

Abstract

Introduction

Rheumatoid arthritis (RA) is a common autoimmune disease typically manifested by symmetric swelling and pain in the small joints of the hands and feet.[1] The lungs are one of the most common extra-articular organs involved in RA.[2,3] Lung involvement is reported to occur in up to 60% to 80% of RA patients. Most people develop pulmonary manifestations after or simultaneously with joint symptoms; however, up to 20% of cases present with thoracic disease followed by articular disease.[2,4] Respiratory complications are the second leading cause of death due to RA.[2]

There is a wide spectrum of RA-associated respiratory diseases [Table 1]. These include interstitial lung diseases (ILD), airway diseases, rheumatoid nodules, pleural diseases, and vasculitis. Thoracic involvement, especially ILD is a marker of poor prognosis in RA patients.[5] Secondary respiratory infection, for example, Pneumocystis jirovecii pneumonia (PJP) and drug-associated pulmonary disease are other common complications of RA patients, which also impact prognosis.[6-9] There has been recent progress in understanding the management and progression of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and RA-associated respiratory diseases. ILD, opportunistic pulmonary infectious diseases, and toxicity from medications are the common causes of diffuse pulmonary disease of RA. Although ILD is the most common manifestation of respiratory involvement of RA, it is important to differentiate RA-ILD from PJP and drug-induced pulmonary disease. Because pulmonologists play an important role during the treatment of RA-associated respiratory diseases, they should have an understanding of these challenging problems.

Table 1 - Spectrum of RA-associated respiratory diseases.
Classifications Diseases
Interstitial lung diseases Usual interstitial pneumonia
Non-specific interstitial pneumonia
Organizing pneumonia
Lymphocytic interstitial pneumonitis
Desquamative interstitial pneumonia
Diffuse alveolar hemorrhage
Pulmonary rheumatoid nodules
Airway disease Bronchiolitis
 Bronchiolitis obliterans
 Follicular bronchiolitis
Bronchiectasis
Pleural disease Pleuritis
Pleural effusion
Pleural rheumatoid nodules
 Pneumothorax
 Bronchopleural fistula
Vascular disease Pulmonary hypertension
Pulmonary vasculitis
Thromboembolic diseases
Malignant diseases Lung cancer
Pulmonary lymphoproliferative disorders
Treatment-associated lung disease Drug-induced lung diseases
Methotrexate pneumonitis
Opportunistic infectious pulmonary diseases
RA: Rheumatoid arthritis.

From a chest physician perspective, we will update the diagnosis and treatment of diffuse lung diseases associated with RA, focusing on RA-associated ILD, methotrexate-associated lung disease, and the complication of PJP in RA.

RA-associated ILD

ILD is the most common manifestation of RA-associated lung disease, and it is a potentially life-threatening complication of RA. ILD is diagnosed in 5% to 63% of RA patients. The prevalence varies depending on whether ILD is defined by chest X ray (<5%), clinical symptoms (10%), pulmonary function tests (PFTs) (33%–41%), or high-resolution computed tomography (HRCT) (20%–63%).[10,11] The reported prevalence of ILD also differs among autopsy, hospital, and community-based studies.[12] For these reasons, it is difficult to definitively define the prevalence of RA-ILD.

Clinical manifestations

The symptoms of RA-ILD are non-specific and insidious and can be masked by joint manifestations that may limit activity. Subclinical ILD has been reported in 19% to 67% of cases.[13] Because of these limitations, early RA-ILD may be unrecognized by clinicians. Delayed diagnosis and treatment of RA-ILD is a poor prognostic factor for RA-ILD. The recognition of risk factors for RA-ILD, sensitive serum biomarkers, for example, anti-cyclic citrullinated peptide (CCP) and Krebs von den Lungen-6 (KL-6), and clinical examination may aid the diagnosis of RA-ILD in early stages.

Screening for ILD has been recommended for RA patients with factors reported to increase the risk for developing ILD. These include a history of current or past smoking, male sex, select human leukocyte antigen (HLA) variants (including HLA-B54, HLA-DQB1∗0601, HLA-B40, and HLA-DR4), high titers of anti-CCP antibody, and presence of the mucin 5 subtype B (MUC5B) promoter variant (rs35705950).[14-16] Detailed inquiry about common ILD symptoms (dry cough, exertional dyspnea, exercise limitation, and auscultatory crackles) is central to the initial diagnostic workup. However, the velcro sound detector and/or transthoracic lung ultrasound could be suggested for rheumatologists to screen ILD in RA patients.[17-19] PFTs can be used to screen for RA-ILD as they are readily available. However, they are relatively insensitive to the presence of early ILDs. For example, it has been reported that 40 of 64 patients (62.5%) with significant ILD on HRCT had a normal forced vital capacity, and two showed normal values for all PFTs measures.[20] HRCT is more sensitive to screening ILDs and is a key test to evaluate ILDs. To identify ILDs, PFTs and chest HRCT are recommended for RA patients with suspected ILD after detailed clinical appraisal.[13,21,22] However, chest HRCT was a more sensitive and convincing examination than PFT to identify the ILD.

Morphological characters

The usual interstitial pneumonia (UIP) pattern and non-specific interstitial pneumonia (NSIP) pattern of ILD are the common pathological and chest radiological morphological patterns for the RA-ILD.[23-29] The chest HRCT of UIP and NSIP patterns are shown in Figure 1. The presence of honeycombing and a UIP pattern are also poor prognostic factors for RA-ILD.[28,30,31] An organizing pneumonia (OP) pattern is a less common morphological pattern of RA-ILD.[25,32] Rheumatoid nodules, lymphocytic interstitial pneumonia, diffuse alveolar hemorrhage, and desquamative interstitial pneumonia are rare morphological features of RA-ILD.[3,33] Compared with other connective tissue diseases (CTD), small airway diseases, including bronchiolitis obliterans, follicular bronchiolitis, and bronchiectasis, are more common in RA patients.[33,34] Some patients may have coexisting interstitial and small airways disease or diffuse bronchiectasis in RA and RA-ILD[35,36]: a recent meta-analysis showed that the overall prevalence of bronchiectasis is between 18.7% and 22.6%, and bronchiectasis is more common in RA-ILD (18.1%–30.0%) vs. RA without ILD (10.5%–20.0%). As ILD can be the first manifestation of RA, for patients with a UIP and/or NSIP pattern of ILD concomitant with bronchiectasis, screening for RA in the initial diagnostic algorithm and follow-up surveillance is recommended for patients with a UIP or NSIP pattern of ILD.

F1
Figure 1:
The chest high-resolution computed tomography characteristics of UIP and NSIP. (A) UIP: basal predominant subpleural reticulation with honeycombing (arrowheads) and traction bronchiectasis (arrows). (B) NSIP: interlobular septal thickening with subpleural GGO and the absence of honeycombing. GGO: Ground glass opacities; NSIP: Non-specific interstitial pneumonia; UIP: Usual interstitial pneumonia.

Evaluation and diagnosis

RA-ILD should be differentiated from drug-induced ILD and secondary pulmonary infections, especially opportunistic pulmonary infections (eg, PJP, cytomegaovirus, and aspergillosis) in patients treated with immunosuppressants. Both non-biologic disease-modifying antirheumatic drugs (DMARDs) and biologic disease-modifying antirheumatic drugs can induce ILD during the RA treatment.[7,37,38] Drug-induced ILD usually has an acute/subacute course and is characterized by fever, dyspnea, with diffuse ground glass opacities (GGO) on HRCT in the context of medication use.[39] It should be differentiated from the opportunistic pulmonary infection, especially PJP. Bronchoalveolar lavage fluid (BALF) analysis and bacterial culture can be used to rule out infection in difficult cases.

Similar to the diagnostic algorithm of idiopathic pulmonary fibrosis (IPF),[40] a multidisciplinary discussion with input from pulmonologists, thoracic radiologists, pathologists, and rheumatologists (when available) is also recommended for the diagnosis of RA-ILD. Rheumatologists and pulmonologists often collaborate during management and follow-up of RA-ILD patients.

Treatment and prognosis

There are no randomized clinical trials guiding treatment of RA-ILD. Therefore, treatment decisions are currently based on clinical experience. For those with significant active RA-related inflammatory and joint symptoms, the rheumatologists typically take the main responsibility and DMARDs and/or glucocorticoids were the main medications for RA-ILD. However, for those with ILD-dominant RA, pulmonologists may lead the management of RA-ILD. The morphologic pattern of RA-ILD may be considered in the treatment protocol.[41] For patients with a UIP pattern, DMARDs and/or glucocorticoids might not be the first choice; however, anti-fibrotic medications, including nintedanib and pirfenidone, are preferred for management, especially in cases where physiologic progression is documented. Recent clinical trials using antifibrotic medications for progressive fibrosing ILD with variable causes (including RA-ILD) demonstrated that they may slow the decline of pulmonary function.[42-44] To explore the efficiency of pirfenidone for RA-ILD, a phase 2 clinical trial is ongoing.[45] For patients with an NSIP or OP pattern, both glucocorticoids and DMARDs may be useful. The initial doses and protocol of glucocorticoids treatment could refer to the treatment of cryptogenic organizing pneumonia or idiopathic NSIP or CTD-ILD[46-49]: start at a prednisone equivalent of 0.5 to 1.0 mg·kg−1·day−1 according to the activity and severity of the ILD. Non-anti-tumor necoris factor DMARDs may reduce the risk of lung disease progression.[50] As there is no randomized clinical trial investigating the efficacy of glucocorticoid-sparing immunosuppressants for RA-ILD, many different immunosuppressants including mycophenolate mofetil, cyclophosphamide, tacrolimus, and cyclosporine A, have been used for managing RA-ILD. Tocilizumab and abatacept may be effective for RA-ILD.[51-53] Lung transplantation may be considered for managing the end-stage RA-ILD. The one-year survival of RA-ILD patients managed with lung transplant is reportedly similar to IPF patients.[54]

Acute exacerbations, secondary pulmonary infections, and malignancy are additional complications of RA-ILD.[55-60] In the Izuka's retrospective study, RA-ILD in a UIP pattern was associated with the acute exacerbations and death.[57] Furthermore, patients with RA-ILD in a UIP pattern had a similar clinical phenotype and prognosis to patients with IPF.[30,61-63] Although the survival of RA-ILD has improved since the use of DMARDs, ILD remains a potentially life-threatening complication of RA.[64,65] Identifying potential future progression of RA-ILD can be challenging. The MUC5B rs35705950 promoter variant was not associated with the prognosis of RA-ILD.[66] A UIP pattern,[30,61-63] older age, male sex, smoking history, lower pulmonary function index,[67-69] and high serum KL-6 levels are poor prognostic factors for RA-ILD.[70]

MTX Pneumonitis in RA

Methotrexate (MTX) was the first conventional DMARD for RA. However, diffuse pulmonary disease had been reported to be an adverse effect of MTX. Since the first report of MTX pneumonitis in 1969, several hundred cases have been described. The frequency of MTX pneumonitis is reported as 0.3% to 11.6%. It typically presents as a subacute process of cough, dyspnea, and diffuse GGO and/or consolidation, frequently with fever and progression over several weeks. Although there are cases of late-onset pneumonitis, approximately 50% of cases are diagnosed within 32 weeks of starting MTX.[71]

Older age, diabetes, rheumatoid pleuropulmonary involvement, previous use of DMARDs, hypoalbuminemia, and HLA-A31:01 haplotype are reported risk factors for MTX pneumonitis.[72] Because of the potential for pneumonitis, MTX was not recommended for treatment of RA-ILD. However, this practice has been questioned because recent studies suggest that MTX might delay the onset or progression of ILD in RA patients,[73] and MTX has not been found to be a risk factor for RA-ILD.[73-75]

A hypersensitivity reaction, direct cytotoxic effect, and idiosyncratic immune reaction are proposed mechanisms of MTX pneumonitis.[39,76] Analysis of BALF from patients with MTX pneumonitis typically reveals a lymphocytosis with elevated CD4/CD8 ratio; however, some studies report a neutrophilic pattern and variable CD4/CD8 ratio.[77-79] Although the BALF analysis is not diagnostic, it may be useful for differentiating from opportunistic pulmonary infections. Histopathologically, an interstitial infiltrate by lymphocytes and granuloma formation is classic pathologic features of MTX-induced pneumonitis.[76] In addition, type II pneumocyte proliferation, tissue eosinophilia, organizing diffuse alveolar damage, and perivascular (predominantly perivenular) inflammation have all been described in MTX pneumonitis.[80-82] Chest imaging typically reveals diffuse ground-glass opacities, occasionally with regions of consolidation, septal thickening, and reticular shadows.[82,83] Traction bronchiectasis may be found in cases of chronic disease.[83]

Proposed diagnostic criteria for MTX pneumonitis include exposure to MTX preceding the onset of pulmonary symptoms (cough, dyspnea, and/or fever) with new or evolving opacities on chest radiographs, lung pathology consistent with drug-induced lung toxicity, and exclusion of pulmonary infections, especially PJP or alternative pulmonary diseases, including RA-ILD, pulmonary alveolar hemorrhage, or other drug-induced lung diseases.[82,84] Typically RA-ILD is more chronic and insidious in onset than MTX pneumonitis and pulmonary infection. PJP is a serious complication to consider during MTX administration for RA patients because the clinical and radiological features of MTX pneumonitis and PJP may be similar.[8,85] Elevation of serum 1,3-β-D-glucan (βDG) and positive results of microbiological examinations with respiratory specimens including sputum or BALF are helpful to differentiate the presence of PJP.

Monitoring the pulmonary symptoms during follow-up for RA patients administrated with MTX, especially during the first year, is recommended. Early recognition and diagnosis of MTX pneumonitis may prevent progression of lung injury to a life-threatening adverse event. MTX pneumonitis typically resolves following discontinuation of MTX and glucocorticoids.[84] Immunosuppressants such as cyclophosphamide and tocilizumab may be used in severe or rapidly progressive cases where the mortality rate may be as high as 17.6%.[39] Although there are case reports of successful re-challenge of MTX for recovered RA-MTX pneumonitis patients, it is probably best to avoid re-introduction of MTX for those who have suffered from MTX pneumonitis.

PJP and RA-ILD

The incidence of PJP in RA patients (RA-PJP) treated with DMARDs is 0.1% to 0.4% and is associated with a relatively high mortality rate (10%–20%). Age >65 years, oral prednisolone ≥5 mg/day, use of DMARDs (both traditional and biological), preexisting lung disease, lower peripheral blood lymphocyte count, low serum immunoglobulin G levels, and asymptomatic carriers of Pneumocystis jirovecii, are risk factors for PJP in RA.[86-88] Although the prognosis of PJP has improved, it is worse for RA-PJP than non-RA-PJP.[89] Prophylactic administration of trimethoprim–sulfamethoxazole (TMP-SMX) is recommended for RA patients with more than one risk factor for PJP.[9]

Dry cough, dyspnea, hypoxia, and fever are common clinical manifestations of PJP. Radiographically, diffuse GGO, consolidations, and fine reticulation are chest CT manifestations of PJP.[8,9] Remarkably, these findings can be similar to RA-ILD. Thus, it may be challenging for physicians to differentiate the two conditions by clinical and/or radiological features alone. Symmetric, perihilar, and apical predominant distribution of GGO, usually with peripheral sparing, is the typical chest imaging of non-human immunodeficiency virus (HIV)-PJP.[90] The lung opacities typically resolve after treatment; however, progression to a mosaic pattern with architectural distortion or consolidation without effective management has been reported.[90] Focal or lower lobe predominant distribution, nodules, septal thickening, or cysts are unusual chest CT manifestations of non-HIV-PJP.

Traditionally, Gomori-methenamine-silver (GMS) staining of sputum or BALF was used for PJP diagnosis; however, it has low sensitivity in non-HIV patients. Respiratory specimens polymerase chain reaction detection for PJP-DNA is more sensitive: the sensitivity ranges from 87% to 100%, with nearly a 100% negative predictive rate.[91] Anti-PJP monoclonal antibody with immunofluorescent stains is also reported to have a higher sensitivity and specificity than GMS staining. Elevated serum βDG and lactate dehydrogenase are useful biomarkers for the PJP diagnosis.[92]

Because a delay in the initiation of antimicrobial for PJP is associated with poor prognosis, anti-PJP treatment should be started for RA-PJP as soon as the disease is considered, even prior to diagnosis. TMP-SMX at a dose of trimethoprim 5 to 20 mg · kg−1 · day−1 is the standard treatment for PJP. Potential adverse events of TMP-SMX including skin rash, bone marrow suppression, or liver injury, should be monitored for carefully. As TMP-SMX may magnify the hematological toxicity of MTX, the combination of MTX with TMP-SMX should be avoided. Caspofungin, pentamidine, atovaquone, or clindamycin–primaquine are alternative therapeutic choices.[93] The adjunctive use of glucocorticoids and tapering protocol should be individualized for RA-PJP, considering the activity and severity of RA and RA-associated complications. Poor prognostic factors include older age, lymphopenia, pneumothorax or pneumomediastinum, intensive care unit admission, and concomitant ILD.

Conclusions

ILD is the most common respiratory complication of RA, and it is associated with poor prognosis. However, it is important to differentiate RA-ILD from opportunistic pulmonary infections and pulmonary toxicity from RA treatment medications. Individualized management is indicated once the final diagnosis is established. The activity and severity of RA and ILD should be considered during management of RA-ILD. For those with ILD-dominant RA, pulmonologists should consider the morphologic pattern of ILD. Antifibrotic medications might be used for those with progressive fibrosing ILD.

Funding

The study was supported by the the National High Level Hospital Clinical Research Funding (No. 2022-PUMCH-A-009) and the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (No. 2019XK320037).

Conflicts of interest

None.

References

1. Sparks JA. Rheumatoid arthritis. Ann Intern Med 2019;170:ITC1–ITC16. doi: 10.7326/AITC201901010.
2. Figus FA, Piga M, Azzolin I, McConnell R, Iagnocco A. Rheumatoid arthritis: extra-articular manifestations and comorbidities. Autoimmun Rev 2021;20:102776. doi: 10.1016/j.autrev.2021.102776.
3. Esposito AJ, Chu SG, Madan R, Doyle TJ, Dellaripa PF. Thoracic manifestations of rheumatoid arthritis. Clin Chest Med 2019;40:545–560. doi: 10.1016/j.ccm.2019.05.003.
4. Sparks JA, Jin YZ, Cho SK, Vine S, Desai R, Doyle TJ, et al. Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients. Rheumatology (Oxford) 2021;60:3689–3698. doi: 10.1093/rheumatology/keaa836.
5. Reid P, Guler SA. Mortality trends in rheumatoid arthritis: zooming in on interstitial lung disease. Ann Am Thorac Soc 2021;18:1953–1954. doi: 10.1513/AnnalsATS.202108-899ED.
6. Saravanan V, Kelly C. Drug-related pulmonary problems in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006;45:787–789. doi: 10.1093/rheumatology/kel075.
7. Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum 2014;43:613–626. doi: 10.1016/j.semarthrit.2013.09.005.
8. LeMense GP, Sahn SA. Opportunistic infection during treatment with low dose methotrexate. Am J Respir Crit Care Med 1994;150:258–260. doi: 10.1164/ajrccm.150.1.8025760.
9. Sonomoto K, Tanaka H, Nguyen TM, Yoshinari H, Nakano K, Nakayamada S, et al. Prophylaxis against pneumocystis pneumonia in rheumatoid arthritis patients treated with b/tsDMARDs: insights from 3787 cases in the FIRST registry. Rheumatology (Oxford) 2022;61:1831–1840. doi: 10.1093/rheumatology/keab647.
10. Antin-Ozerkis D, Evans J, Rubinowitz A, Homer RJ, Matthay RA. Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med 2010;31:451–478. doi: 10.1016/j.ccm.2010.04.003.
11. Cassone G, Manfredi A, Vacchi C, Luppi F, Coppi F, Salvaeani C, et al. Treatment of rheumatoid arthritis-associated interstitial lung disease: lights and shadows. J Clin Med 2020;9:1082. doi: 10.3390/jcm9041082.
12. Lake F, Proudman S. Rheumatoid arthritis and lung disease: from mechanisms to a practical approach. Semin Respir Crit Care Med 2014;35:222–238. doi: 10.1055/s-0034-1371542.
13. Spagnolo P, Lee JS, Sverzellati N, Rossi G, Cottin V. The lung in rheumatoid arthritis: focus on interstitial lung disease. Arthritis Rheumatol 2018;70:1544–1554. doi: 10.1002/art.40574.
14. Manfredi A, Cassone G, Luppi F, Atienza-Mateo B, Cavazza A, Sverzellati N, et al. Rheumatoid arthritis related interstitial lung disease. Expert Rev Clin Immunol 2021;17:485–497. doi: 10.1080/1744666X.2021.1905524.
15. Dai Y, Wang W, Yu Y, Hu S. Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology, pathogenesis and management. Clin Rheumatol 2021;40:1211–1220. doi: 10.1007/s10067-020-05320-z.
16. Kamiya H, Panlaqui OM. Systematic review and meta-analysis of the risk of rheumatoid arthritis-associated interstitial lung disease related to anti-cyclic citrullinated peptide (CCP) antibody. BMJ Open 2021;11:e040465. doi: 10.1136/bmjopen-2020-040465.
17. Manfredi A, Cassone G, Cerri S, Venerito V, Fedele AL, Trevisani M, et al. Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: the InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device). BMC Pulm Med 2019;19:111. doi: 10.1186/s12890-019-0875-x.
18. Moazedi-Fuerst FC, Kielhauser SM, Scheidl S, Tripolt NJ, Lutfi A, Yazdani-Biuki B, et al. Ultrasound screening for interstitial lung disease in rheumatoid arthritis. Clin Exp Rheumatol 2014;32:199–203.
19. Pancaldi F, Sebastiani M, Cassone G, Luppi F, Cerri S, Della Casa G, et al. Analysis of pulmonary sounds for the diagnosis of interstitial lung diseases secondary to rheumatoid arthritis. Comput Biol Med 2018;96:91–97. doi: 10.1016/j.compbiomed.2018.03.006.
20. Yiannakis EP, Boswell TC. Systematic review of outbreaks of Pneumocystis jirovecii pneumonia: Evidence that P. jirovecii is a transmissible organism and the implications for healthcare infection control. J Hosp Infect 2016;93:1–8. doi: 10.1016/j.jhin.2016.01.018.
21. Spagnolo P, Ryerson CJ, Putman R, Oldham J, Salisbury M, Sverzellati N, et al. Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities. Lancet Respir Med 2021;9:1065–1076. doi: 10.1016/S2213-2600(21)00017-5.
22. Richeldi L, Cottin V, Würtemberger G, Kreuter M, Calvello M, Sgalla G. Digital lung auscultation: will early diagnosis of fibrotic interstitial lung disease become a reality? Am J Respir Crit Care Med 2019;200:261–263. doi: 10.1164/rccm.201902-0306LE.
23. Tanaka N, Kim JS, Newell JD, Brown KK, Cool CD, Meehan R, et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology 2004;232:81–91. doi: 10.1148/radiol.2321030174.
24. Yousem SA, Colby TV, Carrington CB. Lung biopsy in rheumatoid arthritis. Am Rev Respir Dis 1985;131:770–777. doi:10.1164/arrd.1985.131.5.770.
25. Suda T. Up-to-date information on rheumatoid arthritis-associated interstitial lung disease. Clin Med Insights Circ Respir Pulm Med 2016;9:155–162. doi: 10.4137/CCRPM.S23289.
26. Lee HK, Kim DS, Yoo B, Seo JB, Rho JY, Colby TV, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005;127:2019–2027. doi: 10.1378/chest.127.6.2019.
27. Assayag D, Elicker BM, Urbania TH, Colby TV, Kang BH, Ryu JH, et al. Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Radiology 2014;270:583–588. doi: 10.1148/radiol.13130187.
28. Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, Van Uden JH, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010;35:1322–8. doi: 10.1183/09031936.00092309.
29. Groner LK, Green DB, Weisman SV, Legasto AC, Toy D, Gruden JF. Thoracic manifestations of rheumatoid arthritis. Radiographics 2021;41:32–55. doi: 10.1148/rg.2021200091.
30. Yamakawa H, Sato S, Nishizawa T, Kawabe R, Oba T, Kato A, et al. Impact of radiological honeycombing in rheumatoid arthritis-associated interstitial lung disease. BMC Pulm Med 2020;20:25. doi: 10.1186/s12890-020-1061-x.
31. Wakabayashi A, Ishiguro T, Takaku Y, Miyahara Y, Kagiyama N, Takayanagi N. Clinical characteristics and prognostic factors of pneumonia in patients with and without rheumatoid arthritis. PLoS One 2018;13:e0201799. doi: 10.1371/journal.pone.0201799.
32. Okada H, Kurasawa K, Yamazaki R, Tanaka A, Arai S, Owada T, et al. Clinical features of organizing pneumonia associated with rheumatoid arthritis. Mod Rheumatol 2016;26:863–868. doi: 10.3109/14397595.2016.1153217.
33. Alunno A, Gerli R, Giacomelli R, Carubbi F. Clinical epidemiological and histopathological features of respiratory involvement in rheumatoid arthritis. Biomed Res Int 2017;2017:7915340. doi: 10.1155/2017/7915340.
34. Perez T, Remy-Jardin M, Cortet B. Airways involvement in rheumatoid arthritis: clinical, functional, and HRCT findings. Am J Respir Crit Care Med 1998;157:1658–1665. doi: 10.1164/ajrccm.157.5.9710018.
35. Martin LW, Prisco LC, Huang W, McDermott G, Shadick NA, Doyle TJ, et al. Prevalence and risk factors of bronchiectasis in rheumatoid arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum 2021;51:1067–1080. doi: 10.1016/j.semarthrit.2021.08.005.
36. Cortet B, Perez T, Roux N, Flipo RM, Duquesnoy B, Delcambre B, et al. Pulmonary function tests and high-resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis 1997;56:596–600. doi: 10.1136/ard.56.10.596.
37. Hadjinicolaou AV, Nisar KM, Bhagat S, Parfrey H, Chilvers ER, Östör AJK. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases – A systematic literature review. Rheumatology (Oxford) 2011;50:2297–2305. doi: 10.1093/rheumatology/ker289.
38. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bove A, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011;41:256–264. doi: 10.1016/j.semarthrit.2010.11.002.
39. Fragoulis GE, Nikiphorou E, Larsen J, Korsten P, Conway R. Methotrexate-associated pneumonitis and rheumatoid arthritis-interstitial lung disease: current concepts for the diagnosis and treatment. Front Med (Lausanne) 2019;6:238. doi: 10.3389/fmed.2019.00238.
40. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An Official ATS/ERS/JRS/ALAT Statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788–824. doi: 10.1164/rccm.2009-040GL.
41. Huang SC, Kronzer VL, Dellaripa PF, Deane KD, Bolster MB, Nagaraja V, et al. Rheumatoid arthritis-associated interstitial lung disease: current update on prevalence, risk factors, and pharmacologic treatment. Curr Treat Opt Rheumatol 2020;6:337–353. doi: 10.1007/s40674-020-00160-z.
42. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019;381:1718–1727. doi: 10.1056/NEJMoa1908681.
43. Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 2020;8:147–157. doi: 10.1016/S2213-2600 (19)30341-8.
44. Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 2020;8:453–460. doi: 10.1016/S2213-2600(20)30036-9.
45. Solomon JJ, Danoff SK, Goldberg HJ, Woodhead F, Kolb M, Chambers DC, et al. The design and rationale of the Trail1 trial: a randomized double-blind phase 2 clinical trial of pirfenidone in rheumatoid arthritis-associated interstitial lung disease. Adv Ther 2019;36:3279–3287. doi: 10.1007/s12325-019-01086-2.
46. Travis WD, Hunninghake G, King TE Jr, Lynch DA, Colby TV, Galvin JR, et al. Idiopathic nonspecific interstitial pneumonia: report of an American thoracic society project. Am J Respir Crit Care Med 2008;177:1338–1347. doi: 10.1164/rccm.200611-1685OC.
47. Cordier JF. Cryptogenic organizing pneumonia. Clin Chest Med 2004;25:727–738. doi: 10.1016/j.ccm.2004.06.003.
48. Chartrand S, Fischer A. Management of connective tissue disease-associated interstitial lung disease. Rheum Dis Clin North Am 2015;41:279–294. doi: 10.1016/j.rdc.2015.01.002.
49. Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ 2016;352:h6819. doi:10.1136/bmj.h6819.
50. Mena-Vázquez N, Godoy-Navarrete FJ, Manrique-Arija S, Aguilar-Hurtado MC, Romero-Barco CM, Ureñate-Garnica I, et al. Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis. Clin Rheumatol 2021;40:133–142. doi: 10.1007/s10067-020-05227-9.
51. Manfredi A, Cassone G, Furini F, Gremese E, Venerito V, Atzeni F, et al. Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. Intern Med J 2020;50:1085–1090. doi: 10.1111/imj.14670.
52. Fernández-Díaz C, Castañeda S, Melero-González RB, Oetiz-Sanjuán F, Juan-Mas A, Carrasco-Cubero C, et al. Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients. Rheumatology (Oxford) 2020;59:3906–3916. doi: 10.1093/rheumatology/keaa621.
53. Vicente-Rabaneda EF, Atienza-Mateo B, Blanco R, Cavagna L, Ancochea J, Castañeda S, et al. Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: a systematic literature review. AutoimmunRev 2021;20:102830. doi: 10.1016/j.autrev.2021.102830.
54. Yazdani A, Singer LG, Strand V, Gelber AC, Williams L, Mittoo S. Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation. J Hear Lung Transplant 2014;33:514–520. doi: 10.1016/j.healun.2014.01.858.
55. Coyne P, Hamilton J, Heycock C, Saravanan V, Coulson E, Kelly CA. Acute lower respiratory tract infections in patients with rheumatoid arthritis. J Rheumatol 2007;34:1832–1836.
56. Yoshida Y, Takahashi Y, Minemura N, Ueda Y, Yamashita H, Kaneko H, et al. Prognosis of pneumocystis pneumonia complicated in patients with rheumatoid arthritis (RA) and non-RA rheumatic diseases. Mod Rheumatol 2012;22:509–514. doi: 10.1007/s10165-011-0523-7.
57. Izuka S, Yamashita H, Iba A, Takahashi Y, Kaneko H. Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: clinical features and prognosis. Rheumatology (Oxford) 2021;60:2348–2354. doi: 10.1093/rheumatology/keaa608.
58. Wu X, Peng H, Wen Y, Cai X, Li C, Zhong R, et al. Rheumatoid arthritis and risk of lung cancer: meta-analysis and Mendelian randomization study. Semin Arthritis Rheum 2021;51:565–575. doi: 10.1016/j.semarthrit.2021.03.015.
59. Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther 2015;17:212. doi: 10.1186/s13075-015-0728-9.
60. Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol 2016;35:2585–2589. doi: 10.1007/s10067-016-3357-z.
61. Ekici M, Baytar Y, Kardas RC, Sari A, Akdogan A, Durhan G, et al. Predictors of mortality in rheumatoid arthritis-associated lung disease: a retrospective study on ten years. Joint Bone Spine 2021;88:105133. doi: 10.1016/j.jbspin.2021.105133.
62. Kakutani T, Hashimoto A, Tominaga A, Kodama K, Nogi S, Tsuno H, et al. Related factors, increased mortality and causes of death in patients with rheumatoid arthritis-associated interstitial lung disease. Mod Rheumatol 2020;30:458–464. doi: 10.1080/14397595.2019.1621462.
63. Jacob J, Hirani N, van Moorsel CHM, Rajagopalan S, Murchison JT, van Es HW, et al. Predicting outcomes in rheumatoid arthritis related interstitial lung disease. Eur Respir J 2019;53:1800869. doi: 10.1183/13993003.00869-2018.
64. Kelly CA, Nisar M, Arthanari S, Carty S, Woodhead FA, Price-Forbes A, et al. Rheumatoid arthritis related interstitial lung disease – improving outcomes over 25 years: a large multicentre UK study. Rheumatology (Oxford) 2021;60:1882–1890. doi: 10.1093/rheumatology/keaa577.
65. Jeganathan N, Nguyen E, Sathananthan M. Rheumatoid arthritis and associated interstitial lung disease: mortality rates and trends. Ann Am Thorac Soc 2021;18:1970–1977. doi: 10.1513/AnnalsATS.202102-115OC.
66. Juge PA, Solomon JJ, van Moorsel CHM, Garofoli R, Lee JS, Louis-Sydney F, et al. MUC5B promoter variant rs35705950 and rheumatoid arthritis associated interstitial lung disease survival and progression. Semin Arthritis Rheum 2021;51:996–1004. doi: 10.1016/j.semarthrit.2021.07.002.
67. Qiu M, Jiang J, Nian X, Wang Y, Yu P, Song J, et al. Factors associated with mortality in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. Respir Res 2021;22:264. doi: 10.1186/s12931-021-01856-z.
68. Gao J, Xin L, Guo Q, Xu K, Zhang G, Yang Y, et al. Twenty-year changes in mortality rates and underlying causes of death in patients with rheumatoid arthritis-associated interstitial lung disease. Scand J Rheumatol 2021;50:360–364. doi: 10.1080/03009742.2021.1882557.
69. Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Patterns of interstitial lung disease and mortality in rheumatoid arthritis. Rheumatology (Oxford) 2017;56:344–350. doi: 10.1093/rheumatology/kew391.
70. Kim HC, Choi KH, Jacob J, Song JW. Prognostic role of blood KL-6 in rheumatoid arthritis-associated interstitial lung disease. PLoS One 2020;15:e0229997. doi: 10.1371/journal.pone.0229997.
71. Kremer JM, Alarcón GS, Weinblatt ME, Kaymakcian MV, Macaluso M, Cannon GW, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997;40:1829–1837. doi: 10.1002/art.1780401016.
72. Alarcón GS, Kremer JM, Macaluso M, Weinblatt ME, Cannon GW, Palmer WR, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: a multicenter, case-control study. Ann Intern Med 1997;127:356–364. doi: 10.7326/0003-4819-127-5-199709010-00003.
73. Juge PA, Lee JS, Lau J, Kawano-Dourado L, Rojas Serrano J, Sebastiani M, et al. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J 2021;57:2000337. doi: 10.1183/13993003.00337-2020.
74. Kiely P, Busby AD, Nikiphorou E, Sullivan K, Walsh DA, Creamer P, et al. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ Open 2019;9:e028466. doi: 10.1136/bmjopen-2018-028466.
75. Ibfelt EH, Jacobsen RK, Kopp TI, Cordtz RL, Jakobsen AS, Seersholm N, et al. Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study. Rheumatology (Oxford) 2021;60:346–352. doi: 10.1093/rheumatology/keaa327.
76. Leduc D, De Vuyst P, Lheureux P, Gevenois PA, Jacobovitz D, Yernault JC. Pneumonitis complicating low-dose methotrexate therapy for rheumatoid arthritis: discrepancies between lung biopsy and bronchoalveolar lavage findings. Chest 1993;104:1620–1623. doi: 10.1378/chest.104.5.1620.
77. Fuhrman C, Parrot A, Wislez M, Prigent H, Boussaud V, Bernaudin JF, et al. Spectrum of CD4 to CD8 T-cell ratios in lymphocytic alveolitis associated with methotrexate-induced pneumonitis. Am J Respir Crit Care Med 2001;164:1186–1191. doi: 10.1164/ajrccm.164.7.2010120.
78. Schnabel A, Richter C, Bauerfeind S, Gross WL. Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis. Thorax 1997;52:377–379. doi: 10.1136/thx.52.4.377.
79. D’Elia T. Methotrexate-induced pneumonitis: heterogeneity of bronchoalveolar lavage and differences between cancer and rheumatoid arthritis. Inflamm Allergy Drug Targets 2014;13:25–33. doi: 10.2174/1871528112666131230013059.
80. Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol 1987;14:1164–1171.
81. Flieder DB, Travis WD. Pathologic characteristics of drug-induced lung disease. Clin Chest Med 2004;25:37–45. doi: 10.1016/S0272-5231(03)00138-2.
82. Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J 2000;15:373–381. doi: 10.1034/j.1399-3003.2000.15b25.x.
83. Arakawa H, Yamasaki M, KuriharaY, Yamada H, Nakajima Y. Methotrexate-induced pulmonary injury: serial CT findings. J Thorac Imaging 2003;18:231–236. doi: 10.1097/00005382-200310000-00004.
84. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 2004;43:143–147. doi: 10.1093/rheumatology/keg466.
85. Tokuda H, Sakai F, Yamada H, Johkoh T, Imamura A, Dohi M, et al. Clinical and radiological features of pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study. Intern Med 2008;47:915–923. doi: 10.2169/internalmedicine.47.0702.
86. Yukawa K, Nagamoto Y, Watanabe H, Funaki M, Iwahashi M, Yamana J, et al. Risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis and a prophylactic indication of trimethoprim/sulfamethoxazole. J Clin Rheumatol 2018;24:355–360. doi: 10.1097/RHU.0000000000000731.
87. Mori S, Sugimoto M. Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis. Rheumatology (Oxford) 2012;51:2120–2130. doi: 10.1093/rheumatology/kes244.
88. Mori S, Sugimoto M. Pneumocystis jirovecii pneumonia in rheumatoid arthritis patients: risks and prophylaxis recommendations. Clin Med Insights Circ Respir Pulm Med 2015;9:29–40. doi: 10.4137/CCRPM.S23286.
89. Komano Y, Harigai M, Koike R, Sugiyama H, Ogawa J, Saito K, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Care Res 2009;61:305–312. doi: 10.1002/art.24283.
90. Cereser L, Dallorta A, Candoni A, Volpetti S, Righi E, Zuiani C, et al. Pneumocystis jirovecii pneumonia at chest high-resolution computed tomography (HRCT) in non-HIV immunocompromised patients: spectrum of findings and mimickers. Eur J Radiol 2019;116:116–127. doi: 10.1016/j.ejrad.2019.04.025.
91. Li MC, Lee NY, Lee CC, Lee HC, Chang CM, Ko WC. Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals. J Microbiol Immunol Infect 2014;47:42–47. doi: 10.1016/j.jmii.2012.08.024.
92. Sun R, Lv D, Xiao M, Zhang L, Xu J, Yu X, et al. Diagnostic accuracy of the 1,3-beta-d-glucan test and lactate dehydrogenase for pneumocystis pneumonia in non-HIV patients. Sci Rep 2021;11:9226. doi: 10.1038/s41598-021-88729-z.
93. Catherinot E, Lanternier F, Bougnoux ME, Lecuit M, Couderc LJ, Lortholary O. Pneumocystis jirovecii pneumonia. Infect Dis Clin North Am 2010;24:107–138. doi: 10.1016/j.idc.2009.10.010.
Keywords:

Interstitial lung disease; Lung; Methotrexate pneumonitis; Pneumocystis jiroveci pneumonia; Rheumatoid arthritis

Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.